Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma, a specialty pharmaceutical company, has introduced its lead product Loramyc in the British, German and Danish markets.
Subscribe to our email newsletter
BioAlliance Pharma’s Loramyc is now available in four European countries and will be commercialized in the UK, Germany and Denmark by SpeBio.
With the UK, Germany and Denmark, BioAlliance Pharma is extending its European presence and, with SpeBio, is actively preparing market launches in additional European countries to take place before the end of 2008.
Dominique Costantini, president and CEO of BioAlliance Pharma, said: “This simultaneous product launch in three European countries crowns the efforts of our teams and marks another concrete step in the internationalization of our business. In these three countries, we are going to fully leverage our initial experience with the product in France.”